KalVista Pharmaceuticals Statistics
Total Valuation
KALV has a market cap or net worth of $387.21 million. The enterprise value is $219.19 million.
Important Dates
The next estimated earnings date is Thursday, December 5, 2024, before market open.
| Earnings Date | Dec 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
KALV has 43.22 million shares outstanding. The number of shares has increased by 30.92% in one year.
| Current Share Class | 43.22M |
| Shares Outstanding | 43.22M |
| Shares Change (YoY) | +30.92% |
| Shares Change (QoQ) | +6.06% |
| Owned by Insiders (%) | 1.70% |
| Owned by Institutions (%) | 71.71% |
| Float | 23.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.23 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.55, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.55 |
| Quick Ratio | 8.32 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -90.84% and return on invested capital (ROIC) is -59.58%.
| Return on Equity (ROE) | -90.84% |
| Return on Assets (ROA) | -53.94% |
| Return on Capital (ROIC) | -59.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$945,133 |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.35% in the last 52 weeks. The beta is 0.91, so KALV's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +10.35% |
| 50-Day Moving Average | 11.06 |
| 200-Day Moving Average | 12.18 |
| Relative Strength Index (RSI) | 30.21 |
| Average Volume (20 Days) | 408,601 |
Short Selling Information
The latest short interest is 6.87 million, so 15.90% of the outstanding shares have been sold short.
| Short Interest | 6.87M |
| Short Previous Month | 6.81M |
| Short % of Shares Out | 15.90% |
| Short % of Float | 29.71% |
| Short Ratio (days to cover) | 24.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | -93.47M |
| Operating Income | -155.57M |
| Pretax Income | -126.64M |
| Net Income | -141.77M |
| EBITDA | -154.72M |
| EBIT | -155.57M |
| Earnings Per Share (EPS) | -$3.57 |
Full Income StatementBalance Sheet
The company has $174.27 million in cash and $6.25 million in debt, giving a net cash position of $168.02 million or $3.89 per share.
| Cash & Cash Equivalents | 174.27M |
| Total Debt | 6.25M |
| Net Cash | 168.02M |
| Net Cash Per Share | $3.89 |
| Equity (Book Value) | 172.80M |
| Book Value Per Share | 4.01 |
| Working Capital | 169.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$102.72 million and capital expenditures -$57,000, giving a free cash flow of -$102.78 million.
| Operating Cash Flow | -102.72M |
| Capital Expenditures | -57,000 |
| Free Cash Flow | -102.78M |
| FCF Per Share | -$2.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |